Enlivex Revenue and Competitors

Nes-Ziona,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Enlivex's estimated annual revenue is currently $12.5M per year.(i)
  • Enlivex's estimated revenue per employee is $201,000

Employee Data

  • Enlivex has 62 Employees.(i)
  • Enlivex grew their employee count by -15% last year.

Enlivex's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Enlivex?

Our mission is to establish new equilibriums – both in patients' immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body's native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated. Highlights: * Advanced clinical-stage pipeline with promising Phase II results * Short regulatory approval pathway * Multi-billion-dollar markets: Post-BMT complications , Sepsis, Solid tumors

keywords:N/A

N/A

Total Funding

62

Number of Employees

$12.5M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Enlivex News

2022-04-20 - Zacks: Brokerages Expect Enlivex Therapeutics Ltd ...

Zacks: Brokerages Expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Will Post Earnings of -$0.26 Per Share. Posted by admin on Apr 22nd, 2022.

2022-04-13 - Should Biotechnology Stock Enlivex Therapeutics Ltd (ENLV) Be in Your Portfolio Thursday?

Should Biotechnology Stock Enlivex Therapeutics Ltd (ENLV) Be in Your Portfolio Thursday? The 64 rating InvestorsObserver gives to Enlivex...